Dr. Amrein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St Yaw 7
Hematology Oncology
Boston, MA 02114Phone+1 617-726-8748Fax+1 617-643-1915
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1977 - 1980
- Yale-New Haven Medical Center (Waterbury)Residency, Internal Medicine, 1974 - 1977
- Johns Hopkins University School of MedicineClass of 1974
Certifications & Licensure
- MA State Medical License 1979 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Teaching Award APP Group at MGH, 2021
- The One Hundred MGH Cancer Center, 2016
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 1998 Jan 01
- Dasatinib in Relapsed Chronic Lymphocytic Leukemia Start of enrollment: 2006 Dec 01
- VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia Start of enrollment: 2003 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsMulticenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.Amir T Fathi, Haesook T Kim, Robert J Soiffer, Mark J Levis, Shuli Li
Clinical Cancer Research. 2023-06-01 - 4 citationsIxazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.Philip Amrein, Karen Ballen, Kristen Stevenson, Andrew Brunner, Gabriela Hobbs
Leukemia & Lymphoma. 2022-06-01 - A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.Joan How, Siyang Ren, Jennifer Lombardi-Story, Meghan Bergeron, Julia Foster
Ejhaem. 2022-05-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: